RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Dr Reddy's Laboratories Stock

Dr Reddy's Laboratories Net Income 2024

Dr Reddy's Laboratories Net Income

55.78 B INR

Ticker

DRREDDY.NS

ISIN

INE089A01023

WKN

659157

In 2024, Dr Reddy's Laboratories's profit amounted to 55.78 B INR, a 23.75% increase from the 45.07 B INR profit recorded in the previous year.

The Dr Reddy's Laboratories Net Income history

YEARNET INCOME (undefined INR)
2028e-
2027e49.59
2026e60.73
2025e58.23
202455.78
202345.07
202221.83
202119.52
202020.26
201919.5
20189.47
201712.92
201621.31
201523.36
201419.63
201315.27
201213.01
20119.99
20103.52
2009-9.17
20084.38
20079.66
20061.47
20050.33

Dr Reddy's Laboratories Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Dr Reddy's Laboratories, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Dr Reddy's Laboratories from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Dr Reddy's Laboratories’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Dr Reddy's Laboratories. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Dr Reddy's Laboratories’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Dr Reddy's Laboratories’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Dr Reddy's Laboratories’s growth potential.

Dr Reddy's Laboratories Revenue, EBIT and net profit per share

DateDr Reddy's Laboratories RevenueDr Reddy's Laboratories EBITDr Reddy's Laboratories Net Income
2028e372.73 B undefined85.85 B undefined0 undefined
2027e332.39 B undefined59.22 B undefined49.59 B undefined
2026e343.11 B undefined73.72 B undefined60.73 B undefined
2025e316.04 B undefined71.39 B undefined58.23 B undefined
2024280.11 B undefined64.63 B undefined55.78 B undefined
2023246.7 B undefined52.9 B undefined45.07 B undefined
2022215.45 B undefined35.33 B undefined21.83 B undefined
2021190.48 B undefined33.22 B undefined19.52 B undefined
2020175.17 B undefined29.91 B undefined20.26 B undefined
2019154.48 B undefined20.55 B undefined19.5 B undefined
2018142.81 B undefined12.74 B undefined9.47 B undefined
2017141.96 B undefined14.9 B undefined12.92 B undefined
2016155.68 B undefined30.8 B undefined21.31 B undefined
2015150.23 B undefined27.48 B undefined23.36 B undefined
2014134.15 B undefined26.03 B undefined19.63 B undefined
2013118.96 B undefined21.73 B undefined15.27 B undefined
201298.15 B undefined19.17 B undefined13.01 B undefined
201174.97 B undefined11.55 B undefined9.99 B undefined
201070.31 B undefined10.14 B undefined3.52 B undefined
200969.01 B undefined9.56 B undefined-9.17 B undefined
200849.92 B undefined4.39 B undefined4.38 B undefined
200765.26 B undefined12.85 B undefined9.66 B undefined
200623.63 B undefined1.52 B undefined1.47 B undefined
200518.42 B undefined-332 M undefined329 M undefined

Dr Reddy's Laboratories stock margins

The Dr Reddy's Laboratories margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Dr Reddy's Laboratories. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Dr Reddy's Laboratories.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Dr Reddy's Laboratories's sales revenue. A higher gross margin percentage indicates that the Dr Reddy's Laboratories retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Dr Reddy's Laboratories's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Dr Reddy's Laboratories's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Dr Reddy's Laboratories's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Dr Reddy's Laboratories. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Dr Reddy's Laboratories's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Dr Reddy's Laboratories Margin History

Dr Reddy's Laboratories Gross marginDr Reddy's Laboratories Profit marginDr Reddy's Laboratories EBIT marginDr Reddy's Laboratories Profit margin
2028e68.08 %23.03 %0 %
2027e68.08 %17.82 %14.92 %
2026e68.08 %21.49 %17.7 %
2025e68.08 %22.59 %18.43 %
202468.08 %23.07 %19.91 %
202366.34 %21.44 %18.27 %
202262.88 %16.4 %10.13 %
202165.54 %17.44 %10.25 %
202065.68 %17.07 %11.57 %
201967.77 %13.3 %12.62 %
201868.35 %8.92 %6.63 %
201770.36 %10.5 %9.1 %
201671.33 %19.78 %13.69 %
201570.7 %18.29 %15.55 %
201468.7 %19.41 %14.63 %
201366.57 %18.26 %12.83 %
201269.75 %19.53 %13.25 %
201169.2 %15.41 %13.32 %
201063.7 %14.42 %5 %
200962.89 %13.86 %-13.29 %
200863.04 %8.79 %8.78 %
200756.21 %19.69 %14.8 %
200663.27 %6.42 %6.21 %
200566.01 %-1.8 %1.79 %

Dr Reddy's Laboratories Aktienanalyse

What does Dr Reddy's Laboratories do?

Dr. Reddy's Laboratories Ltd is an Indian pharmaceutical company that was founded in 1984 by Dr. K. Anji Reddy. The company started as a small laboratory in Hyderabad, India and quickly grew to become one of the leading global pharmaceutical companies. History The company began as a chemical research institute specializing in the development of high-quality generics and new drugs. Dr. Reddy's Laboratories was one of the first companies in India to begin manufacturing and exporting generics on a large scale. Today, the company operates in over 100 countries worldwide and employs over 21,000 people. Business Model The company's business model focuses on developing high-quality and affordable medications to improve the lives of patients worldwide. The company invests millions of dollars annually in research and development of new drugs to provide people with innovative and better treatment options. Various Divisions Dr. Reddy's Laboratories is divided into several business divisions, including: - Generics: A key business factor is generic production, including various dosages and forms of oral solid or liquid medications. - Biosimilars: Dr. Reddy's Laboratories has several biosimilars in its portfolio, including Epoetin alfa, Darbepoetin alfa, and Pegfilgastim, used for treating various diseases and conditions. - Specialty Products: The company also offers a variety of specialty products, particularly in the field of oncology. Products Over the years, Dr. Reddy's Laboratories has developed many innovative, high-quality, and affordable medications. Some of the company's most well-known products include: - Omez: A popular gastric medication used to treat heartburn and reflux. - Norflox: An antibiotic used to treat bacterial infections. - Reditux: A biosimilar of the antibody Rituximab used in cancer treatment. - Librium: A medication used for anxiety and depression. Conclusion Dr. Reddy's Laboratories is a global company specializing in the research, development, and manufacturing of innovative, high-quality, and affordable medications. The company has a long history in generic production and the manufacturing of specialty products and biosimilars. Through its research and development programs, the company constantly strives to meet the needs of patients and provide them with better healthcare. Dr Reddy's Laboratories ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Dr Reddy's Laboratories's Profit Margins

The profit margins of Dr Reddy's Laboratories represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Dr Reddy's Laboratories's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Dr Reddy's Laboratories's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Dr Reddy's Laboratories's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Dr Reddy's Laboratories’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Dr Reddy's Laboratories stock

How much profit has Dr Reddy's Laboratories made this year?

Dr Reddy's Laboratories has made 55.78 B INR this year.

How has the profit developed compared to last year?

The profit has increased by 23.75% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Dr Reddy's Laboratories publish its earnings?

Dr Reddy's Laboratories publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Dr Reddy's Laboratories?

The profits of Dr Reddy's Laboratories are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Dr Reddy's Laboratories?

You can learn more about the earnings of Dr Reddy's Laboratories by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Dr Reddy's Laboratories pay?

Over the past 12 months, Dr Reddy's Laboratories paid a dividend of 40 INR . This corresponds to a dividend yield of about 0.59 %. For the coming 12 months, Dr Reddy's Laboratories is expected to pay a dividend of 43.54 INR.

What is the dividend yield of Dr Reddy's Laboratories?

The current dividend yield of Dr Reddy's Laboratories is 0.59 %.

When does Dr Reddy's Laboratories pay dividends?

Dr Reddy's Laboratories pays a quarterly dividend. This is distributed in the months of August, August, August, August.

How secure is the dividend of Dr Reddy's Laboratories?

Dr Reddy's Laboratories paid dividends every year for the past 0 years.

What is the dividend of Dr Reddy's Laboratories?

For the upcoming 12 months, dividends amounting to 43.54 INR are expected. This corresponds to a dividend yield of 0.65 %.

In which sector is Dr Reddy's Laboratories located?

Dr Reddy's Laboratories is assigned to the 'Health' sector.

Wann musste ich die Aktien von Dr Reddy's Laboratories kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Dr Reddy's Laboratories from 8/28/2024 amounting to 40 INR, you needed to have the stock in your portfolio before the ex-date on 7/16/2024.

When did Dr Reddy's Laboratories pay the last dividend?

The last dividend was paid out on 8/28/2024.

What was the dividend of Dr Reddy's Laboratories in the year 2023?

In the year 2023, Dr Reddy's Laboratories distributed 40 INR as dividends.

In which currency does Dr Reddy's Laboratories pay out the dividend?

The dividends of Dr Reddy's Laboratories are distributed in INR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Dr Reddy's Laboratories

Our stock analysis for Dr Reddy's Laboratories Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dr Reddy's Laboratories Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.